) mice provide a model of prolonged GSH depletion to explore the relationship between GSH, complex I inhibition, and dopamine loss in vivo. Despite ~60% depletion of brain GSH in Gclm −/− mice of ages 3-5 or 14-16 months, striatal complex I activity, dopamine levels, 3-nitrotyroine/tyrosine ratios, aconitase activity, and CoASH remained unchanged. Administration of paraquat (10 mg/kg, twice/week, 3 weeks) to 3-to 5-month-old Gclm −/− mice resulted in significantly decreased aconitase activity, complex I activity, and dopamine levels but not in 3-to 5-month-old Gclm +/+ mice. Furthermore, paraquat-induced inhibition of complex I and aconitase activities in Gclm −/− mice was observed in the striatum but not in the cortex. The results suggest that chronic deficiency of GSH in Gclm −/− mice was not sufficient to result in complex I inhibition or dopamine depletion perhaps due to homeostatic mechanisms but required an additional oxidative stress insult as shown with paraquat exposure.
Environmental factors such as herbicide and pesticide exposure have been linked to the etiology of Parkinson's disease (PD). PD is a progressive, age-related neurodegenerative disorder characterized by selective depletion of dopamine in the striatum caused by loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) (Brown et al., 2006; Calne and Langston, 1983) . 1,1′-Dimethyl-4,4′-bipyridinium (paraquat, PQ), a redoxcycling herbicide, has been implicated in environmental causes of PD based on its ability to replicate PD-like neurodegeneration in rodents. Although PQ toxicity is thought to primarily involve the lung, significant brain damage is observed in individuals exposed to lethal doses (Brooks et al., 1999; Grant et al., 1980; Hughes, 1988; McCormack et al., 2002) . In fact, epidemiological studies suggest an increased risk for developing PD following chronic PQ exposure (Hertzman et al., 1990; Liou et al., 1997) . The mechanisms of PQ-induced neurodegeneration remain to be determined but are likely related to the compound's ability to generate reactive oxygen species (ROS) via redox cycling (Bus and Gibson, 1984 ). The precise mechanisms by which pesticides and other environmental factors contribute to the dopaminergic cell death are unresolved. Oxidative stress, complex I inhibition, and mitochondrial dysfunction arising from environmental and/ or genetic factors are the leading mechanisms suggested in the pathogenesis of dopaminergic neuronal death associated with PD (Beal, 2001; Dauer and Przedborski, 2003; Greenamyre et al., 2001; Jenner et al., 1992; Schapira et al., 1992) . Numerous studies have demonstrated that complex I inhibition and glutathione (GSH) depletion are chief among the mechanisms by which mitochondrial dysfunction and oxidative stress are thought to play a perpetrating role in causing dopaminergic defects in PD, respectively (Dauer and Przedborski, 2003; Greenamyre et al., 2001; Jenner et al., 1992; Perry and Yong, 1986; Schapira et al., 1990) . GSH is the most abundant nonprotein thiol and a major antioxidant that functions to maintain the redox equilibrium in cells. Depletion of GSH levels by 40-50% have been reported in autopsied brains of patients with PD by several laboratories Pearce et al., 1997; Perry et al., 1982; Riederer et al., 1989; Sofic et al., 1992) . In fact, some studies GLUTATHIONE DEFICIENCY AND PARAQUAT TOXICITY suggest that GSH depletion may be one of the earliest detectable biomarkers in the PD SNpc preceding selective decreases in mitochondrial complex I activity and striatal dopamine loss (Sian et al., 1994) . The selective complex I inhibition in the SNpc has been demonstrated in postmortem analysis of tissue from PD patients (Schapira et al., 1990) . Importantly, Parkinsonian toxicants such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and rotenone, which are known complex I inhibitors, induce dopaminergic neuron death further supporting the role of impaired complex I in PD pathogenesis (Betarbet et al., 2000; Langston, 1996) . Additionally, complex I is the most severely impaired respiratory chain complex causing age-related mitochondrial dysfunction (Lenaz et al., 1997) .
Oxidative damage has been implicated as a leading mechanism by which the complex I defect occurs in PD (Keeney et al., 2006) ; however, the precise mechanism(s) and identity of reactive species causing the damage remain to be determined. The role of GSH in causing complex I inhibition in PD has gained interest based on studies demonstrating that depletion of GSH levels by buthionine sulfoximine (BSO), a glutamate cysteine ligase (GCL) inhibitor, in PC12 or N27 cells in vitro (Chinta and Andersen, 2006; Hsu et al., 2005; Jha et al., 2000) or by inducible GSH deficiency within dopaminergic neurons of mouse in vivo (Chinta et al., 2007) results in selective inhibition of complex I activity. However, in vivo studies in which depletion of GSH was induced by stereotaxic BSO injection in adult rats (Seaton et al., 1996; Toffa et al., 1997) or sc administration in neonatal rats (Heales et al., 2011) failed to demonstrate inhibition of mitochondrial respiratory complexes. GSH depletion has also been observed in incidental Lewy body disease, which is believed to represent presymptomatic PD, in the absence of complex I inhibition (Sian et al., 1994) . Therefore, whether depletion of GSH itself induces complex I inhibition and striatal dopamine loss needs further clarification.
Although the GCL inhibitor BSO provides a useful tool to acutely deplete GSH in vivo, it has been suggested that its ability to cross the blood-brain barrier is limited (Griffith and Meister, 1979) , necessitating its use in neonatal rather than adult animals (Andersen et al., 1996; Heales et al., 1995 Heales et al., , 2011 Jain et al., 1991) or by stereotaxic administration in adult rats' brain (Seaton et al., 1996; Toffa et al., 1997) . The rate-limiting enzyme in GSH biosynthesis is GCL, which is a heterodimeric protein composed of catalytic (GCLC) and modifier (GCLM) subunits that are expressed from different genes. Deletion of the Gclm gene leads to significantly lower GSH concentration in all of the tissues including the brain (Franklin et al., 2009; McConnachie et al., 2007) . Gclm null (Gclm −/− ) mice provide a normal and prolonged GSH depletion model to explore the effect of GSH on mechanisms of global oxidative stress and its relationship to dopaminergic dysfunction.
The goal of this study was to determine whether chronic GSH deficiency in Gclm −/− mice results in complex I inhibition and/or dopamine depletion and whether these indices were further potentiated by systemic administration of PQ.
MATErIALS AnD METHoDS
Mice. Animal studies were carried out in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals . All procedures were approved by the Institute Animal Care and Use Committee (IACUC) of University of Colorado Denver (UCD), which is fully accredited by the American Association for the Accreditation of Laboratory Animal Care. Gclm −/− mice on a C57BL/6 background were transferred to UCD from the University of Washington.
Genotyping. Genotyping of pups was carried out following the method described before by analyzing for the presence of both the native Gclm gene and β-geo sequences in two separate PCR reactions (McConnachie et al., 2007) . The reactions utilized the same Gclm forward primer 5′-GCC CGC TCG CCA TCT CTC-3′; the β-geo sequence was detected with the reverse primer 5′-CAG TTT GAG GGG ACG ACG ACA-3′ and the native Gclm sequence was detected with the reverse primer 5′-GTT GAG CAG GTT CCC GGT CT-3′. PQ administration. Gender and age-matched male and female Gclm wildtype (+/+) or null (−/−) mice (3-5 and 14-16 months old) were injected sc with PQ at 10 mg/kg in saline (or saline vehicle alone), twice per week for 3 consecutive weeks. Animals were sacrificed 24 h after the last injection of saline or PQ for dopamine levels, oxidative stress makers, and enzyme activities.
Measurement of PQ.
The level of PQ in the brain was quantified by highperformance liquid chromatography (HPLC) with UV detection following a previously described method (Paixão et al., 2002) with small modifications. Briefly, PQ was analyzed on a 5600 CoulArray HPLC (ESA, Chelmsford, MA) using a 5µM, 150 × 4.6 mm C-18 reversed-phase YMC-ODS column (Waters Com., Milford, MA) equipped with a UV detector set at 258 nm. The mobile phase was composed of 5% methanol, 3mM sodium octanesulphonate, and 0.1M orthophosphoric acid, adjusted to pH 3.0 with diethylamine. The brain tissue was sonicated in 0.1N PCA and centrifuged at 13,000 × g at 4°C for 15 min to precipitate protein. Aliquots (20 µl) of the supernatant were injected into the HPLC.
Measurement of dopamine.
Striatal dopamine and DOPAC levels were determined using a previously described method using an HPLC equipped with an electrochemical detector (Liang and Patel, 2004) .
Measurement of oxidative stress makers. GSH, glutathione disulfide (GSSG), tyrosine, and 3-nitrotyrosine (3-NT) assays were performed with an ESA 5600 CoulArray HPLC equipped with eight electrochemical cells as previously described (Beal et al., 1990; Hensley et al., 1998; Liang et al., 2007) . The potentials of the electrochemical cells were set at 0/150/300/450/570/690/800/850 mV. Analyte separation was conducted on a TOSOHAAS (Montgomeryville, PA) reverse-phase ODS 80-TM C-18 analytical column (4.6 mm × 250 cm; 5 µm particle size). A two-component gradient elution system was used with component A of the mobile phase composed of 50mM NaH 2 PO 4 , pH 3.2, and component B composed of 50mM NaH 2 PO 4 and 40% methanol, pH 3.2. An aliquot (40 µl) of the supernatant was injected into the HPLC. The level of 3-NT was expressed as the ratio of 3-NT to tyrosine.
Measurement of reduced coenzyme A (CoASH) and its mixed disulfide with GSH (CoASSG).
CoASH and CoASSG were measured by HPLC with UV detection as previously described (Liang and Patel, 2006) .
Isolation of mitochondrial-enriched fractions.
Mitochondrial-enriched fractions (crude mitochondria) were isolated from the cortex or striata of mice as in previously described methods in which we have characterized purity using immunoblot analysis (Liang and Patel, 2006) . Both activities of aconitase and complex I were performed in mitochondrial-enriched fraction from a pair of striata or entire cortex of the mouse.
Aconitase activity assay. Aconitase activity in mitochondrial fractions was measured as previously described (Patel et al., 1996) . One unit was defined as the amount of enzyme necessary to produce 1 µmol cis-aconitate per minute (ξ 240 = 3.6 mM −1 ).
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Complex I activity assay. Complex I (NADH:ubiquinone oxidoreductase, EC 1.6.99.3) activity was measured in mitochondrial fractions as previously described (Birch-Machin and Turnbull, 2001; Liang and Patel, 2004) . The reaction was initiated by the addition of 50 µg protein brain mitochondria to the assay buffer (25mM KH 2 PO 4 , 5mM MgCl 2 , pH 7.4, containing 65µM ubiquinone, 130µM NADH, 2 µg/ml antimycin A, and 2.5 mg/ml defatted BSA). The oxidation of NADH was monitored spectrophotometrically at 340 nm for 2 min at 30°C. Activity was further monitored for 2 min following the addition of rotenone (2 µg/ml). The difference between the rate of oxidation before and after the addition of rotenone was used to calculate complex I activity.
Statistical analyses. For comparison among the differences of gene and treatment groups, two-way ANOVA with Bonferroni posttest was used. Values of p < 0.05 were considered significant.
rESuLTS
GSH and GSSG levels were measured to determine intracellular thiol redox status in the brains of Gclm null mice. GSH levels were depleted ~8 and ~62% in the striata of 3-to 5-month-old Gclm −/+ and Gclm −/− mice, respectively, in comparison with age-matched Gclm +/+ mice (Fig. 1A) . GSSG levels were not significantly altered in the striata of 3-to 5-monthold Gclm −/+ and Gclm −/− mice in comparison with age-matched Gclm +/+ mice although a small but no significant decrease was found in Gclm −/− mice (Fig. 1B) . When expressed as a percentage of total GSH, the % GSSG levels in the striata of Gclm −/− mice were doubled compared with those of Gclm +/+ and Gclm −/+ mice (Fig. 1C) . Biological reductive potential (GSSG/2GSH), a crucial determinant of intracellular oxidative conditions, has been widely used as an important index of tissue redox potential and has certain advantages over some other redox pairs (Dalton et al., 2004; Weldy et al., 2012) . Calculation of the redox potentials of GSSG/2GSH (ΔE GSSG/2GSH ) in the striata of Gclm
, and Gclm −/− mice was carried out using the brain cytosolic conditions at pH 7.2 and 37°C. ΔE GSSG/2GSH revealed values of striatal redox potential of Gclm +/+ to be −238.3 ± 2.84 mV (SEM, n = 6). According to previous literature (Dalton et al., 2004) and our experience, the brain has the lowest ΔE GSSG/2GSH redox potential compared with other organs, including liver, kidney, lung, pancreas, spleen, heart, red blood cells, and plasma. ΔE GSSG/2GSH was significantly increased in the striata of Gclm −/− mice but not in the striata of Gclm −/+ mice relative to Gclm +/+ mice (Fig. 1D ). GSH and GSSG alterations occurred in the cortex and ventral midbrain similar to those observed in the striata in 3-to 5-month-old Gclm −/+ and Gclm −/− mice in comparison with age-matched Gclm +/+ mice (data not shown).
No further GSH depletion occurred in the striata of 14-to 16-month-old Gclm +/+ and Gclm −/− mice in comparison with 3-to 5-month-old mice of the same genotype ( Fig. 2A) . Interestingly, no alterations in striatal complex I activity were observed in 3-to 5-month-old or 14-to 16-month-old Gclm −/− mice compared with age-matched Gclm +/+ mice (Fig. 2B) . Similarly, no alterations in striatal dopamine levels were observed in Gclm −/− mice regardless of age and genotype (Fig. 2C) .
CoASH is primarily compartmentalized within mitochondria where its redox status is influenced by that of GSH. The measurement of CoASH in whole tissue provides a reliable intramitochondrial redox status estimation to overcome artifactual changes in GSH oxidation during subcellular fractionation (O'Donovan et al., 2002) . The levels of CoASH were decreased to a minor extent (~10%) in the striata of 3-to 5-month-old Gclm −/− mice in comparison with agematched Gclm +/+ mice, and no further decrease was observed in the striata of 14-to 16-month-old Gclm +/+ or Gclm −/− mice compared with the striata of the 3-to 5-month-old mice (Fig. 3A) . No alterations in the activity of either mitochondrial aconitase (an enzyme known for its high sensitivity to O 2 − -and ONOO − -mediated inactivation; Gardner and Fridovich 1992; Liang and Patel 2006; Patel et al. 1996) or 3-NT (a marker of nitrative stress) in the striata of mice regardless of age or genotype (Figs. 3B and C) .
In summary, despite ~60% depletion of brain GSH in Gclm −/− mice of 3-5 and 14-16 months, striatal complex I activity, dopamine levels, 3-nitrotyroine/tyrosine ratios, and aconitase activity remained unchanged. Therefore, we asked whether these parameters were altered in Gclm −/− mice following administration of PQ, a redoxcycling herbicide that is known to increase steady-state O 2 − and H 2 O 2 . We first confirmed the ability of PQ to access the brain by measuring PQ concentrations in plasma and in different brain regions of wild-type mice. Measurable PQ concentrations were detected in the brain but not in the plasma 72 h after a single dose (10 mg/kg sc) most likely due to clearance from plasma and uptake into tissues such as the brain. The concentrations of PQ in ventral midbrain and striatum were about 2-3 times higher than those observed in the cortex at the majority of the time points (Fig. 4A ). This suggests that PQ accumulates over time in the brain particularly in regions such as the ventral middle brain and striatum. No significant differences in PQ concentrations were observed between Gclm +/+ and Gclm −/− mice regardless brain regions (Fig. 4B) .
FIG. 1. GSH (A), GSSG (B), %GSSG of total GSH (C), and ΔE GSSG/2GSH (D) in the striatum of 3-to 5-month-old Gclm
Next, we asked whether PQ treatment in vivo in 3-to 5-month-old Gclm mutant mice results in depletion of tissue and/or mitochondrial GSH and downstream consequences of GSH depletion on oxidant-sensitive mitochondrial enzymes. PQ treatment was limited to 3-to 5-month-old rather than 14-to 16-month-old Gclm −/− mice due to a greater than ~50% mortality in aged PQ-treated Gclm −/− mice; the death of 14-to 16-month-old Gclm −/− mice with PQ treatment usually occurred after 4-5 PQ injections, and therefore, the availability of PQ-treated aged Gclm −/− mice was highly limited. PQ treatment did not alter mortality in 14-to 16-month-old Gclm +/+ mice. GSH levels were decreased ~11, 29, and 13.5% in the striata of 3-to 5-month-old Gclm
, and Gclm −/− mice following PQ treatment in comparison with genotype-matched saline control groups, respectively (Fig. 5A ). Among the 3-to 5-month-old mice from the three Gclm genotypes (i.e., Gclm
, and Gclm −/− mice), the extent of striatal GSH depletion was dependent on gene dosage, being greatest in PQ-treated Gclm −/− mice, followed by Gclm −/+ mice, and least in Gclm +/+ mice. Similarly complex I activity was not significantly altered in the striata of PQ-treated Gclm +/+ mice but decreased by ~10% in PQ-treated Gclm −/+ mice and ~22% in PQ-treated Gclm −/− mice compared with genotype-matched control (saline-treated) mice (Fig. 5B) . Striatal dopamine levels were decreased by ~12.8 and ~21.4% in Gclm −/+ and Gclm −/− mice, respectively, but not in Gclm +/+ mice compared with genotype-matched saline control groups (Fig. 5C ). This suggests a correlation between the level of dopamine depletion and complex I inhibition.
FIG. 2. GSH levels (A), complex I activity (B)
, and dopamine levels (C) in the striatum of 3-to 5-month-old and 14-to 16-month-old Gclm +/+ and Gclm −/− mice. Bars represent mean + SEM; a p < 0.05 versus same age Gclm +/+ mice; two-way ANOVA, n = 6-8 mice per group.
FIG. 3.
CoASH levels (A), aconitase activity (B), and 3-NT/tyrosine levels (C) in the striatum of 3-to 5-month-old and 14-to 16-month-old Gclm +/+ and Gclm −/− mice. Bars represent mean + SEM; a p < 0.05 versus same age Gclm +/+ mice; two-way ANOVA, n = 6-8 mice per group.
Striatal CoASH levels were decreased by ~13, 23, and 17% in PQ-treated Gclm
, and Gclm −/− mice, respectively, compared with genotype-matched saline control groups (Fig. 6A) . Mitochondrial aconitase activity was inhibited by ~22% in the striata of PQ-treated Gclm −/− mice but not in that of Gclm +/+ or Gclm −/+ mice compared with genotype-matched saline control groups (Fig. 6B) . Finally, striatal 3-NT levels were increased by ~66, 162, and 188% in 3-to 5-month-old PQ-treated Gclm
, and Gclm −/− mice, respectively, compared with genotype-matched saline control groups (Fig. 6C) .
To determine whether PQ treatment preferentially altered the activities of either complex I and aconitase in the striatum versus the cortex of Gclm −/− mice, we assessed cortical complex I and aconitase activities in 3-to 5-month-old PQ-treated Gclm −/− mice; although striatal complex I and mitochondrial aconitase activities were decreased by 18.0 and 20.6%, respectively (Figs. 7A and B) , neither complex I nor aconitase activities were altered in the cortex of PQ-treated Gclm −/− mice compared with genotype-matched saline control groups (Figs.  7A and B) . All of the Gclm +/+ and Gclm −/+ mice used in the studies were males in both saline and PQ treatment groups. Equal numbers of male and female Gclm −/− mice were used in our studies and subjected to saline and PQ treatment. No significant differences were observed between females and males (Supplemental data 1). Although weight gain in Gclm +/+ , Gclm −/+ , and Gclm −/− mice following saline treatment showed no significant differences, PQ treatment resulted in weight loss of 3.1, 7.8, and 17.9% in Gclm +/+ , Gclm −/+ , and Gclm −/− mice, respectively (Supplemental data 2).
DISCuSSIon
The results of this study illustrate two main points: (1) Chronic deficiency of GSH (~60%) in Gclm −/− mice per se is not sufficient to result in inhibition of mitochondrial complex I and aconitase, increases in 3-NT/tyrosine, or depletion of dopamine in the striata of mice regardless of age; (2) PQ administration in Gclm −/− mice results in inhibition of complex I and aconitase, increases in 3-nitrotyrosine/tyrosine ratios, and depletion of dopamine in the striatum but not in the cortex correlating with its ability to accumulate in the mouse striatum and ventral midbrain but not in the the cortex. Together, this suggests that inhibition of critical mitochondrial targets, oxidative damage, and dopamine depletion occur only when both oxidative stress and a major antioxidant defense, i.e., the GSH system, are compromised. GSH deficiency in the brains of PD patients has been known for more than two decades and was suggested to be one of the earliest detectable biomarkers in the PD SN preceding biochemical hallmarks, i.e., decreases in mitochondrial complex I activity and striatal dopamine loss (Sian et al., 1994) . Depletion of GSH has been suggested to be a major mechanism contributing to oxidative damage to complex I in PD (Chinta and Andersen, 2006; Hsu et al., 2005) . GSH depletion of 30-40% in transgenic mice with inducible downregulation of the catalytic subunit of GCL (GCLC) in catacholaminergic neurons has been shown to have selective complex I inhibition (~26%) and age-related dopamine depletion in the striatum (Chinta et al., 2007) . In this study, using GSH depletion embryonically via targeting the modulatory subunit rather than the catalytic subunit, we failed to observe complex I inhibition or dopamine depletion in the striatum regardless of age and despite > 60% GSH depletion. This may be due to ongoing homeostatic mechanisms resulting from chronic deficiency of Gclm that oppose complex I inhibition and dopamine depletion as observed in the vascular system of both Gclm −/+ and Gclm −/− mice (Weldy et al., 2012) . PQ, a herbicide implicated in environmental causes of PD, produces increased steady-state levels of ROS via a redoxcycling mechanism by accepting electrons from various enzymes (Bus and Gibson, 1984) . Recent studies from our laboratory have implicated mitochondria as a major source of PQ-induced ROS in the brain primarily via complex III of the electron transport chain (ETC) (Castello et al., 2007) . Complex I has also been suggested as a source of electrons for PQ in the mitochondria at high concentrations (Cochemé and Murphy, 2008; Drechsel and Patel, 2009a, b; Fukushima et al., 1993) . Additionally, complex I is a target of oxidative damage (Zhang et al., 1990) . Therefore, the interaction of PQ with mitochondrial ETC complexes remains an important aspect of its toxicity, despite some studies asserting that PQ primarily causes cytosolic oxidative stress (Purisai et al., 2007) . Despite limited studies examining the role of brain mitochondria in PQ toxicity in vivo, it should be recognized that administering a relatively small dose (10 mg/kg) of PQ for several weeks is sufficient for its penetration and accumulation in the brain, resulting in concentrations of ~5-20µM (Liang et al., 2009) . The exacerbation of striatal redox markers (GSH and CoASH), aconitase inactivation, complex I inhibition, and dopamine depletion in Gclm −/− mice compared with Gclm +/+ mice suggests that a two-hit model is needed for PQ to exert significant mitochondrial deficits. The inability to detect differences in striatal PQ concentrations in Gclm −/− versus Gclm +/+ mice suggest that the observed genotype-dependent alterations are not due to differential PQ accumulation.
Interestingly, our data also suggest regional vulnerability of PQ toxicity in the brain. Complex I inhibition and aconitase inactivation occurred in the striatum but not in the cortex of Gclm −/− mice following PQ treatment and correlated with PQ levels in the midbrain (striatum and ventral midbrain vs. cortical) regions. Although the ability of PQ to serve as a substrate for the dopamine transporter (DAT) is controversial, a recent study revealed that the monovalent cation, PQ + , generated by either a reducing agent or an NADPH oxidase in glia, but not the divalent cation form (PQ 2+ ) is a substrate for DAT, resulting in its accumulation in DA (dopaminergic) neurons (Rappold et al., 2011) . This is similar to the proposed mechanism of the well-known Parkinsonian toxicant, MPTP, with which PQ bears a striking resemblance. Given the high density of DAT in the striatum and SN in comparison to the cortex (Ciliax et al., 1999) , it may be possible that PQ + accumulated in DA neurons via DAT along with DA to produce both ROS and inhibition of mitochondrial enzymes. In summary, our study clarifies the role of GSH depletion in mitochondrial impairment during PQ neurotoxicity. The data suggest that mitochondrial redox impairment, damage to mitochondrial targets, and dopamine depletion occur only when both oxidative stress and a major antioxidant defense, i.e., the GSH system, are compromised.
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